Improving depression outcomes among Australian primary care patients: protocol for a cluster randomised controlled trial

Abstract

IntroductionDepression is a common and debilitating condition. In Australia, general practitioners (GPs) are the key providers of depression care. However, available evidence suggests that case finding for depression in primary care is poor. This study will examine whether a systematic approach to screening for depression and assessing patient preferences for depression care improves depression outcomes among primary care patients.Methods and analysisA cluster randomised controlled design will be used with general practice clinics randomly assigned to either the intervention (n=12) or usual care group (n=12). Patients who are aged 18 and older, presenting for general practice care, will be eligible to participate. Eighty-three participants will be recruited at each clinic. Participants will be asked to complete a baseline survey administered on a touch screen computer at their GP clinic, and then a follow-up survey at 3, 6 and 12 months. Those attending usual care practices will receive standard care. GPs at intervention practices will complete an online Clinical e-Audit, and will be provided with provider and patient-directed resources for depression care. Patients recruited at intervention practices who score 10 or above on the Patient Health Questionnaire-9 will have feedback regarding their depression screening results and preferences for care provided to their GP. The primary analysis will compare the number of cases of depression between the intervention and control groups.Ethics and disseminationThe study has been approved by the University of Newcastle Human Research Ethics Committee, and registered with Human Research Ethics Committees of the University of Wollongong, Monash University and University of New South Wales. Results will be disseminated through peer-reviewed journal publications and conference presentations.Trial registration numberACTRN12618001139268; Pre-results.

Prescription patterns in unipolar depression: A nationwide Danish register‐based study of 113,175 individuals followed for 10 years

“…While this may be justifiable and in accordance with guidelines in mild and moderate cases, these data illustrate the paucity of predictors of disease progression and the difficulty of early detection of patients with a developing depression in the primary sector, even in the more severe forms. 24 Surprisingly, even in severe depression, more than half of patients continued their pre-diagnosis antidepressant after being diagnosed with depression in a hospital setting, where shifts to another pharmacological class would most often be clinically reasonable.…”

Prioritising and incentivising productivity within indicator-based approaches to Research Impact Assessment: a commentary

“…For example, a prior systematic review and meta-analysis can demonstrate the requirement for further clinical trial evidence, and therefore, improve the probability that a further trial will generate impact [ 25 ]. Our prior studies found that RIA is predominantly about the incentives established by the RIAF, and the extent to which they align with the incentives within the prevailing research system [ 74 – 76 , 134 ]. To optimise impact, the principles leverage and align with the incentives in the existing grant application and peer review processes.…”

Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review

“…General practitioners (GPs) are often the first level of contact in the Australian healthcare system, with mental health related issues representing one of the most common health issues managed by GPs ( Carey et al, 2020 ). However, implementing PGx-guided mental health treatment poses many challenges to primary healthcare providers–these include the limited knowledge and experience of PGx testing, the evidence basis for its use, and the concerns about how it can be incorporated into current workflow ( Vest et al, 2020 ; Jameson et al, 2021 ).…”